Cleveland BioLabs, Inc. has announced that the Board of Directors has decided to nominate David Hohn, MD, former President of Roswell Park Cancer Institute, to its Board of Directors in the upcoming election to be held at the CBLI annual meeting on June 7, 2011.
Dr. Hohn was recruited to Roswell Park Cancer Institute in 1997 to serve as the Institute's 12th President. Dr. Hohn came to Roswell from the MD Anderson Cancer Center in Houston, Texas, where he served as Vice President for Patient Care from 1993 to 1997.
During his 10 years as President and CEO of Roswell Park, Dr. Hohn achieved landmark legislation, creating a new governance model for the Institute, built new research facilities, and recruited a new leadership team in addition to over 160 new clinical and scientific faculty.
Under his leadership, Roswell Park's position as a leader in the national cancer community was reestablished and its operating budget was tripled to $560 million annually. Between 2009 and 2010, the Institute was awarded $104 million to support research grants and contracts, which more than tripled the awards to the Institute when Dr. Hohn was first appointed.
Dr. Hohn was appointed President Emeritus and Executive Director of Health Policy at Roswell Park Cancer Institute upon his retirement in April 2007. He continues his national leadership role in health policy issues, especially as they relate to cancer research and treatment and the training of the next generation of cancer specialists.
He served for three years as Chairman of the Board of Directors of the National Comprehensive Cancer Network, an alliance of 21 of the world's leading cancer centers, and currently serves on that organization's Executive Committee. In 2007, Dr. Hohn was appointed Vice-Chair of the New York Stem Cell Board, an organization that is promoting and funding stem cell research in New York State. Dr. Hohn has authored numerous peer reviewed publications and pioneered development of new medical and surgical technologies.
Michael Fonstein, Ph.D., President and Chief Executive Officer of Cleveland BioLabs, commented, "We are thrilled to add Dr. Hohn to our Board of Directors and further strengthen our association. We have worked closely with David since he orchestrated our strategic partnership with Roswell Park during his tenure as President. His 30 years of clinical and administrative experience will be invaluable as we move forward in our development."